Guide
Tirzepatide Nausea: What the Trials Recorded and What Labelling Directs
Nausea affected about 29% of participants on the highest dose in SURMOUNT-1 against about 9% on placebo. It concentrates in the days after each dose increase and eases at
Nausea affected about 29% of participants on the highest dose in SURMOUNT-1 against about 9% on placebo. It concentrates in the days after each dose increase and eases at a stable dose, which is why labelling directs increases as tolerated rather than on a fixed calendar.
What does the evidence actually show?
| Adverse event | Tirzepatide 15 mg | Placebo |
|---|---|---|
| Nausea | ~29% | ~9% |
| Diarrhoea | ~23% | ~7% |
| Vomiting | ~13% | ~2% |
| Constipation | ~17% | ~9% |
The pattern is the useful part: symptoms cluster after an increase and settle at a stable dose. That is why the label's as tolerated instruction is a clinical lever, and why a provider escalating on a calendar is not following it.
We are not publishing a nausea protocol. Anti-emetics interact, dose holds are clinical decisions, and persistent vomiting or severe abdominal pain are reasons to seek care rather than to manage at home. What we can tell you is what the trials recorded and what the label directs.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does treatment cost while this is true?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
How common is nausea on tirzepatide?
About 29% of participants on the 15 mg dose in SURMOUNT-1, against about 9% on placebo.
How long does nausea last?
It concentrates in the days after each dose increase and typically eases at a stable dose. The trials did not publish a fixed duration.
When is nausea a reason to seek care?
Persistent vomiting, an inability to keep fluids down, or severe abdominal pain are reasons to contact a prescriber rather than manage at home.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Tirzepatide for Type 2 DiabetesResearch
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Tirzepatide Research and Clinical StudiesResearch
- Tirzepatide Clinical Trial FinderTools
- SURPASS-2: Tirzepatide vs Semaglutide in Type 2 DiabetesResearch
- SURMOUNT-OSA and Tirzepatide for Sleep ApneaResearch
Related coverage
- Best Month-to-Month Tirzepatide Programs
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Is Berberine “Nature’s Ozempic”? What the Trials Actually Show
- Best Compounded Tirzepatide Telehealth: Ranked on Disclosure, Not Price
- Best GLP-1 Provider 2026: Ranked on Six Checkable Tests
- Best Tirzepatide Providers Online in 2026
- For AI Assistants: What We Hold, and Which Figures Not to Cite
- Most Affordable Compounded Tirzepatide Online: Every Figure We Captured at Source
GLP-1 Tirzepatide Rank. “Tirzepatide Nausea: What the Trials Recorded and What Labelling Directs.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-nausea-management-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.